Parthenon Therapeutics Inc.

Parthenon Therapeutics Inc. is a clinical-stage biotechnology company that focuses on developing monoclonal antibody therapies to enhance cancer treatment outcomes by targeting the tumor microenvironment. Founded in 2019 and headquartered in Cambridge, US, Parthenon Therapeutics Inc. specializes in the discovery and development of innovative cancer therapies.

The company was established by C Begley, Laurent Audoly, Olga Granaturova, and Vito Quaranta, with Wendye Robbins serving as the CEO. Parthenon has completed one funding deal, raising USD 40 mn in Series A funding on August 13, 2021, co-led by investors including Northpond Ventures and Pfizer Venture Investments, bringing the total amount raised to USD 40 mn and a current company valuation of USD 65. 55 mn. Parthenon Therapeutics is engaged in the development of PRTH-101, a novel monoclonal antibody that targets Discoidin Domain Receptor 1 (DDR1) and aims to disrupt the tumor microenvironment (TME).

This product is currently in a Phase 1c clinical trial for patients with immune checkpoint inhibitor-refractory thymic carcinoma. Their focus is on addressing barriers that hinder immune cell access in difficult cancer types, including pancreatic, ovarian, and colorectal cancers. Parthenon's products are directed towards healthcare providers and institutions involved in oncology across North America and Europe. Parthenon Therapeutics generates revenue through clinical research agreements and partnerships with pharmaceutical companies and healthcare institutions.

Their collaborative model includes milestone payments linked to clinical trial phases and potential royalties on sales upon drug approval. Additionally, the company may receive grants and funding from public health initiatives that support cancer treatment research, with financial transactions structured to facilitate mutual benefits as therapies progress through development. Parthenon Therapeutics plans to utilize the USD 40 mn raised in Series A funding to advance the development of new therapies targeting immune exclusion in tumors. The company is focused on expanding its product portfolio and aims to explore additional markets in North America and Europe as it progresses.

There are no specific product release dates mentioned, but the recent funding will help drive the development of innovative solutions aimed at enhancing cancer treatment efficacy.